UNSPSC 51172153: Trospium

This classification denotes an antimuscarinic agent with the molecular formula C25H30NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4Y8ORK057, chemically known as 6,10-ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate but generally known as trospium, which bears US NIH Compound Identifier 107979. European Medicines Agency schedules Trospium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05000MIG.

UNSPSC 51172153 Trospium is a Commodity code covering a specific pharmaceutical ingredient used in urinary antispasmodic medications. State and local procurement activity under this code reflects two distinct buying patterns: direct pharmaceutical procurement through cooperative purchasing vehicles serving multiple jurisdictions, and specialized clinical laboratory testing services requiring pharmaceutical-grade specimen collection and analysis. Recent solicitations show county correctional supervision departments and state health agencies acquiring trospium-containing products or related diagnostic and testing infrastructure to support offender drug screening, inmate health management, and broader pharmacy benefit programs serving state employees and beneficiaries. The issuing bodies are diverse — county community supervision and corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances — each buying through different mechanisms but all seeking reliable supply chains and certified vendors with established relationships to authorized wholesalers or clinical laboratories.

Geographic activity centers on Texas and Minnesota, with the most recent concrete opportunity being Collin County Community Supervision and Corrections Department's RFP 2026-327, posted July 9, 2026 with proposals due July 23, 2026, for offender specimen collection and drug testing services (estimated contract value $600,000, two-year term with three optional one-year renewals, commencing September 1, 2026). A second Texas opportunity is the HHS Commission's Request for Information HHS0017013 (April 3, 2026) exploring direct-to-manufacturer prescription programs, which may generate formal solicitations for pharmaceutical supply. Minnesota's MMCAP cooperative issued RFP S1070000015802 (January 20, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities in Minnesota and Oregon. Cooperative purchasing vehicles appear to dominate the higher-volume, lower-touch pharmaceutical procurement lanes, while single-county and state-agency RFPs handle specialized clinical and compliance-driven testing services where vendor qualifications, lab certification, and local staffing weigh heavily in evaluation.